Newly Approved Drug for Metastatic Melanoma Nearly Doubles Median Survival

Researchers from UCLA's Jonsson Comprehensive Cancer Center, together with scientists from 12 other sites in the United States and Australia, report for the first time that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated.

Read the whole article on Newswise - Scinews

More from Newswise - Scinews